Ron Korn

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann et al. · Journal of Nuclear Medicine · 2019 · 249 citations · Full text

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody

Michael D. Farwell, Raymond F. Gamache, Hasan Babazada et al. · Journal of Nuclear Medicine · 2021 · 113 citations · Full text

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

Tony Reid, Bryan Oronsky, Jan Scicinski et al. · The Lancet Oncology · 2015 · 90 citations

Advanced Cancer, Dose-escalation Phase 1, Medicine +7

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer

Gayle Jameson, Erkut Borazanci, Hani M. Babiker et al. · JAMA Oncology · 2019 · 71 citations · Full text

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)

Fabien Ricard, Bruce D. Cheson, Sally F. Barrington et al. · Journal of Nuclear Medicine · 2022 · 43 citations · Full text

Oncologic Imaging, Prognosis, Diagnosis +21